According to the “5-year relative survivalpercentage”reported by the U.S. National Cancer Institute, the highest survivalpattern was observed in women with luminal A subtype (94.4%), followedby the luminal B subtype (90.7%), HER2 subtype (84.8%), and finallyTNBC (77.1%).9 Although mortality has decreaseddue to early detection and increasing therapeutic options, almost30% of patients diagnosed with early stages of breast cancer stilldevelop recurrent or metastatic diseases,9 with 5-year survival rates in those patients of only 27%.21 The gene discussed is ERBB2; the disease is breast carcinoma.